Can growth hormone boost height in children with dwarfism?

NCT ID NCT05353192

Completed Disease control Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing whether daily injections of recombinant human growth hormone can improve growth in children with achondroplasia, a genetic condition that causes short stature. The study will include children aged 2 to 10 who have not previously been treated with growth hormone. Over 52 weeks, researchers will measure changes in growth rate and height to see if the treatment is effective and safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Recombinant human growth hormone
What this could lead to: If effective, this could offer a way to increase growth and height in children with achondroplasia, potentially improving their quality of life.
What could go wrong: This is a small, single-arm study without a placebo group, so results may be less reliable. Growth hormone may not significantly improve height and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

achondroplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACHONDROPLASIA

Contacts and locations

Locations

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, 201102, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.